Clinical Trial Update: A Phase III Safety Study of Ferumoxytol Compared to Ferric Carboxymaltose for the Treatment of Iron Deficiency Anemia (IDA) [Phase 3]

View source ↗

Summary

Phase III safety study comparing ferumoxytol to ferric carboxymaltose in iron deficiency anemia has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Iron Deficiency Anemia

Drugs mentioned

• FERUMOXYTOL (ferumoxytol)
• ferrous carboxymaltose (ferric carboxymaltose)

Snippet

Sponsor: AMAG Pharmaceuticals, Inc. | Conditions: Iron Deficiency Anemia | Phase 3 | Status: COMPLETED | Results posted: 2018-06-11